This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
respiratory syndrome | 4099 |
acute respiratory | 3460 |
severe acute | 2951 |
novel coronavirus | 2610 |
syndrome coronavirus | 2505 |
coronavirus disease | 1643 |
spike protein | 1528 |
middle east | 1309 |
east respiratory | 1258 |
sars coronavirus | 933 |
immune response | 855 |
viral rna | 808 |
cov infection | 778 |
cl pro | 774 |
clinical trials | 773 |
converting enzyme | 726 |
severe covid | 709 |
respiratory tract | 681 |
amino acid | 624 |
coronavirus infection | 618 |
viral load | 617 |
neutralizing antibodies | 602 |
public health | 583 |
host cell | 578 |
immune responses | 555 |
human coronavirus | 528 |
doc id | 514 |
cord uid | 514 |
epithelial cells | 513 |
respiratory distress | 509 |
binding domain | 494 |
viral replication | 492 |
clinical characteristics | 486 |
cov cl | 486 |
infected patients | 480 |
immune system | 479 |
cytokine storm | 473 |
convalescent plasma | 470 |
viral infection | 465 |
host cells | 438 |
spike glycoprotein | 438 |
systematic review | 435 |
receptor binding | 431 |
clinical trial | 429 |
ace receptor | 413 |
human ace | 411 |
distress syndrome | 409 |
sars cov | 399 |
new coronavirus | 397 |
nucleic acid | 396 |
cell entry | 395 |
united states | 390 |
critically ill | 383 |
coronavirus spike | 373 |
world health | 371 |
rna polymerase | 360 |
lung injury | 356 |
type i | 356 |
virus infection | 353 |
viral entry | 352 |
health organization | 351 |
like protease | 349 |
hospitalized patients | 347 |
antibody responses | 347 |
patients infected | 343 |
animal models | 341 |
main protease | 335 |
viral infections | 335 |
innate immune | 335 |
infectious diseases | 335 |
human coronaviruses | 335 |
clinical features | 330 |
monoclonal antibodies | 325 |
neutralizing antibody | 322 |
respiratory disease | 321 |
health care | 316 |
structural proteins | 310 |
vaccine development | 305 |
ill patients | 305 |
antiviral activity | 303 |
influenza virus | 294 |
saudi arabia | 289 |
intensive care | 283 |
monoclonal antibody | 283 |
lopinavir ritonavir | 282 |
cohort study | 278 |
ace expression | 278 |
inflammatory cytokines | 278 |
nucleocapsid protein | 276 |
nervous system | 276 |
risk factors | 272 |
amino acids | 271 |
human transmission | 270 |
upper respiratory | 266 |
dromedary camels | 261 |
confirmed cases | 260 |
may also | 259 |
hong kong | 258 |
infected cells | 255 |
symptom onset | 255 |
rna viruses | 252 |
disease severity | 249 |
viral shedding | 246 |
membrane fusion | 243 |
coronavirus pneumonia | 236 |
antiviral drugs | 231 |
cancer patients | 230 |
coronavirus infections | 228 |
lower respiratory | 227 |
protease inhibitor | 226 |
dependent rna | 225 |
cov spike | 222 |
disease control | 222 |
cleavage site | 221 |
active site | 221 |
mortality rate | 217 |
virus replication | 216 |
viral genome | 214 |
serum samples | 213 |
gene expression | 213 |
human monoclonal | 213 |
sars patients | 211 |
incubation period | 210 |
associated coronavirus | 210 |
severe disease | 209 |
crystal structure | 207 |
respiratory failure | 207 |
cell responses | 202 |
cell lines | 202 |
inflammatory response | 200 |
respiratory symptoms | 198 |
chain reaction | 196 |
spike proteins | 196 |
rhesus macaques | 196 |
closely related | 196 |
pregnant women | 193 |
polymerase chain | 192 |
viral loads | 191 |
molecular docking | 191 |
healthcare workers | 189 |
ebola virus | 188 |
cell culture | 188 |
recent study | 187 |
virus entry | 187 |
copyright holder | 186 |
rights reserved | 186 |
bat origin | 186 |
clinical course | 185 |
performed using | 185 |
protease inhibitors | 185 |
binding affinity | 184 |
mechanical ventilation | 184 |
peer review | 182 |
granted medrxiv | 181 |
author funder | 181 |
respiratory viruses | 180 |
reverse transcription | 178 |
acute lung | 178 |
igg antibodies | 177 |
drug discovery | 177 |
central nervous | 175 |
coronavirus associated | 175 |
potential therapeutic | 174 |
immune cells | 174 |
antibody response | 173 |
human respiratory | 173 |
phylogenetic analysis | 172 |
mouse model | 171 |
drug repurposing | 171 |
chest ct | 171 |
orf ab | 169 |
receptor ace | 168 |
clinical studies | 167 |
dendritic cells | 167 |
severe cases | 167 |
infectious disease | 166 |
tested positive | 165 |
endothelial cells | 164 |
fatality rate | 164 |
high levels | 163 |
authors declare | 162 |
viral proteins | 162 |
infected individuals | 162 |
severe respiratory | 160 |
structural basis | 160 |
cov clpro | 159 |
lung tissue | 158 |
functional receptor | 158 |
close contact | 157 |
related coronavirus | 156 |
case series | 156 |
pneumonia outbreak | 155 |
version posted | 154 |
serine protease | 154 |
clinical symptoms | 154 |
another study | 153 |
increased risk | 153 |
previous studies | 153 |
care unit | 151 |
infected pneumonia | 151 |
new york | 151 |
pl pro | 150 |
rna virus | 149 |
animal model | 148 |
ace receptors | 148 |
antiviral drug | 148 |
respiratory infections | 148 |
genome sequences | 147 |
plasma therapy | 147 |
stem cells | 146 |
cell membrane | 146 |
dna vaccine | 146 |
viral particles | 146 |
airborne transmission | 145 |
confirmed covid | 144 |
vaccine candidates | 143 |
time rt | 143 |
mers coronavirus | 143 |
rna synthesis | 143 |
first case | 142 |
genome sequence | 142 |
social distancing | 142 |
higher risk | 141 |
transmission dynamics | 141 |
receptor recognition | 140 |
important role | 139 |
angiotensin converting | 139 |
vaccine candidate | 139 |
coronavirus replication | 139 |
cell epitopes | 138 |
vero cells | 138 |
binding site | 138 |
stranded rna | 138 |
heart failure | 138 |
electron microscopy | 138 |
probable bat | 137 |
host immune | 137 |
novel human | 137 |
outbreak associated | 136 |
specific antibodies | 136 |
kcal mol | 136 |
spectrum antiviral | 136 |
randomized clinical | 136 |
dipeptidyl peptidase | 135 |
severe pneumonia | 135 |
bat sars | 135 |
vertical transmission | 135 |
angiotensin ii | 134 |
care workers | 134 |
phase i | 134 |
case report | 134 |
clinical manifestations | 134 |
peripheral blood | 133 |
corona virus | 133 |
controlled trial | 133 |
cell line | 132 |
target cells | 131 |
type ii | 131 |
common cold | 129 |
clinically proven | 129 |
highly conserved | 127 |
entry depends | 126 |
observational study | 126 |
hubei province | 126 |
confirmed sars | 125 |
approved drugs | 125 |
test results | 123 |
human sars | 123 |
sequence alignment | 123 |
innate immunity | 122 |
recent studies | 122 |
protective immunity | 122 |
respiratory syncytial | 121 |
proven protease | 121 |
room temperature | 121 |
descriptive study | 120 |
protective equipment | 117 |
global health | 117 |
person transmission | 117 |
syncytial virus | 116 |
nasopharyngeal swab | 116 |
personal protective | 116 |
case fatality | 116 |
cell surface | 116 |
human airway | 115 |
cov infections | 115 |
emerging coronaviruses | 115 |
significantly higher | 114 |
coronavirus sars | 114 |
clinical samples | 113 |
infection control | 113 |
cell types | 113 |
neurological manifestations | 113 |
structural studies | 113 |
terminal domain | 113 |
therapeutic options | 112 |
open reading | 112 |
rna genome | 111 |
clinical specimens | 111 |
adaptive immune | 111 |
retrospective cohort | 111 |
igg antibody | 111 |
human cells | 111 |
including sars | 110 |
previously described | 110 |
control measures | 110 |
medrxiv preprint | 110 |
respiratory illness | 110 |
human population | 109 |
life cycle | 109 |
alveolar damage | 109 |
side effects | 108 |
also found | 108 |
virtual screening | 108 |
hydrogen bonds | 107 |
virus disease | 107 |
cov replication | 107 |
intermediate hosts | 106 |
mental health | 106 |
family cluster | 106 |
large number | 106 |
inflammatory responses | 106 |
pcr testing | 106 |
one study | 106 |
accessory proteins | 105 |
nasopharyngeal swabs | 105 |
inhibitory activity | 105 |
proinflammatory cytokines | 105 |
respiratory droplets | 105 |
highly pathogenic | 105 |
cov infected | 105 |
therapeutic targets | 105 |
clinical signs | 105 |
envelope protein | 105 |
acid residues | 104 |
control group | 104 |
nasal swabs | 104 |
transgenic mice | 104 |
chadox ncov | 103 |
supplementary table | 103 |
pcr test | 103 |
sequence identity | 103 |
among patients | 103 |
treat covid | 103 |
pp ab | 103 |
human immunodeficiency | 103 |
organ failure | 102 |
host response | 102 |
intermediate host | 102 |
human lung | 102 |
gastrointestinal symptoms | 102 |
cov rna | 102 |
positive patients | 101 |
cell receptor | 101 |
based vaccine | 101 |
risk factor | 100 |
immunodeficiency virus | 100 |
infectious virus | 100 |
currently available | 100 |
asymptomatic patients | 99 |
bat coronavirus | 99 |
thermo fisher | 99 |
diffuse alveolar | 99 |
negative results | 99 |
pdb id | 99 |
oral transmission | 99 |
infected mice | 99 |
em structure | 99 |
positive results | 99 |
diagnostic tests | 98 |
respiratory infection | 98 |
inhibit sars | 98 |
phylogenetic tree | 97 |
recently emerged | 97 |
two different | 97 |
i interferon | 97 |
cytokine release | 97 |
traditional chinese | 96 |
cardiovascular disease | 96 |
airway epithelial | 96 |
antibody titers | 96 |
made available | 96 |
creative commons | 96 |
ace protein | 95 |
angiotensin system | 95 |
virus origins | 95 |
data analysis | 94 |
respiratory specimens | 94 |
viral spike | 94 |
detect sars | 94 |
statistically significant | 94 |
bronchoalveolar lavage | 94 |
analysis based | 94 |
different types | 94 |
blood pressure | 93 |
emergency use | 93 |
high risk | 93 |
cell death | 93 |
hepatitis virus | 93 |
clinical outcomes | 93 |
herd immunity | 93 |
spike receptor | 93 |
international license | 92 |
cov strains | 92 |
multiple organ | 92 |
sample collection | 92 |
nonstructural proteins | 92 |
neutralization assay | 91 |
antiviral agents | 91 |
south korea | 91 |
genomic characterisation | 91 |
genome sequencing | 91 |
therapeutic agents | 91 |
general population | 91 |
cell fusion | 91 |
small molecule | 91 |
endoplasmic reticulum | 90 |
stem cell | 90 |
global pandemic | 90 |
live virus | 90 |
even though | 90 |
chinese medicine | 89 |
also reported | 89 |
specific antibody | 89 |
olfactory bulb | 89 |
wide range | 89 |
randomized controlled | 89 |
also known | 89 |
early stages | 89 |
cell cultures | 88 |
several studies | 88 |
mg kg | 88 |
binding energy | 88 |
multiple sclerosis | 88 |
present study | 88 |
dependent enhancement | 88 |
widely used | 88 |
early stage | 87 |
first step | 87 |
sars outbreak | 87 |
human cases | 87 |
lung pathology | 87 |
weight loss | 87 |
oxidative stress | 87 |
may lead | 87 |
coronavirus outbreak | 87 |
olfactory epithelium | 87 |
molecular dynamics | 86 |
taken together | 86 |
natural products | 86 |
competing interests | 86 |
reverse transcriptase | 86 |
rheumatoid arthritis | 85 |
ncov infection | 85 |
prefusion conformation | 85 |
patients may | 85 |
endothelial cell | 85 |
dry cough | 84 |
mouse models | 84 |
diabetes mellitus | 84 |
avian influenza | 84 |
rna extraction | 84 |
reactive protein | 84 |
effectively inhibit | 84 |
viral transmission | 84 |
severe sars | 84 |
mg ml | 84 |
drug candidates | 83 |
time reverse | 83 |
factors associated | 83 |
health emergency | 83 |
fisher scientific | 83 |
urgent need | 82 |
cov nsp | 82 |
key role | 82 |
mild symptoms | 82 |
study showed | 82 |
clinical data | 82 |
animal species | 82 |
previously reported | 82 |
live attenuated | 81 |
influenza viruses | 81 |
infection may | 81 |
host receptor | 81 |
results showed | 81 |
antibody tests | 81 |
mouse hepatitis | 81 |
dengue virus | 81 |
respiratory virus | 81 |
vaccine design | 81 |
pcr assay | 81 |
isothermal amplification | 81 |
viral pneumonia | 80 |
coronavirus vaccine | 80 |
may contribute | 80 |
high viral | 80 |
informed consent | 80 |
pathogenic coronaviruses | 80 |
results suggest | 79 |
blood donors | 79 |
also observed | 79 |
virus particles | 79 |
phase iii | 79 |
antiviral effects | 79 |
necrosis factor | 79 |
two patients | 79 |
patients admitted | 78 |
case reports | 78 |
coronavirus hku | 78 |
treating covid | 78 |
symptomatic patients | 78 |
based vaccines | 78 |
familial cluster | 78 |
cov pl | 78 |
binding sites | 78 |
nucleic acids | 77 |
also showed | 77 |
retrospective study | 77 |
treatment options | 77 |
crucial role | 77 |
mice infected | 77 |
lung cells | 77 |
older adults | 77 |
southern china | 77 |
alveolar epithelial | 77 |
broad spectrum | 77 |
adverse events | 76 |
days post | 76 |
gastrointestinal tract | 76 |
antibody test | 76 |
small molecules | 76 |
time pcr | 76 |
enzymatic activity | 76 |
tract infections | 76 |
membrane protein | 76 |
cleavage sites | 75 |
plasma membrane | 75 |
negative control | 75 |
causative agent | 75 |
viral protein | 75 |
acute phase | 75 |
recombinant sars | 75 |
cl protease | 75 |
sample size | 75 |
bat coronaviruses | 75 |
described previously | 75 |
serological tests | 75 |
patients treated | 75 |
molecular mechanisms | 74 |
mesenchymal stem | 74 |
adverse effects | 74 |
cells expressing | 74 |
virus infections | 74 |
zika virus | 74 |
igm antibodies | 74 |
current pandemic | 74 |
cq hcq | 74 |
sars virus | 74 |
viral clearance | 74 |
drug development | 74 |
ncov spike | 74 |
commercially available | 73 |
transmembrane serine | 73 |
antibody titres | 73 |
lateral flow | 73 |
positive sars | 73 |
data suggest | 72 |
viral envelope | 72 |
mutation rate | 72 |
contact tracing | 72 |
cardiovascular system | 72 |
blood samples | 72 |
cerebrospinal fluid | 72 |
multiple sequence | 71 |
novel sars | 71 |
protease tmprss | 71 |
myocardial injury | 71 |
computed tomography | 71 |
cell rna | 71 |
better understanding | 71 |
related coronaviruses | 71 |
may play | 71 |
emerged novel | 71 |
pulmonary disease | 71 |
drug administration | 71 |
virus transmission | 71 |
chloroquine effectively | 70 |
effective treatment | 70 |
genomic characterization | 70 |
study group | 70 |
phase ii | 70 |
drug design | 70 |
signaling pathways | 70 |
samples collected | 70 |
genomic rna | 70 |
neurological symptoms | 70 |
commonly used | 70 |
class i | 69 |
may cause | 69 |
clinical presentation | 69 |
ng ml | 69 |
serological assays | 69 |
choroid plexus | 69 |
genetic material | 69 |
i ifn | 69 |
early transmission | 69 |
tissue damage | 69 |
post infection | 69 |
potential role | 69 |
like receptor | 69 |
cytokine production | 69 |
crystal structures | 69 |
coronavirus indicating | 69 |
heptad repeat | 68 |
complete genome | 68 |
expression levels | 68 |
respiratory samples | 68 |
pneumonia associated | 68 |
real time | 68 |
hydrogen bond | 68 |
human angiotensin | 68 |
tumor necrosis | 68 |
emerging infectious | 67 |
cells infected | 67 |
virus type | 67 |
study also | 67 |
available data | 67 |
three times | 67 |
biosafety level | 67 |
like coronavirus | 67 |
acid sequence | 67 |
study clinical | 67 |
bat cov | 67 |
stool samples | 67 |
asymptomatic cases | 67 |
tested negative | 66 |
asymptomatic carriers | 66 |
least one | 66 |
cellular receptor | 66 |
clinical study | 66 |
coronavirus entry | 66 |
small intestine | 66 |
release syndrome | 66 |
sars epidemic | 66 |
protein interaction | 66 |
like particles | 66 |
virus may | 66 |
viral nucleic | 66 |
mild covid | 66 |
tissue distribution | 66 |
patients hospitalized | 66 |
clinical improvement | 66 |
infect humans | 66 |
kidney injury | 65 |
well plates | 65 |
pcr assays | 65 |
therapeutic target | 65 |
preliminary report | 65 |
one health | 65 |
direct contact | 65 |
epithelial cell | 65 |
reading frames | 65 |
coronavirus rna | 65 |
lung damage | 65 |
respiratory viral | 65 |
long structural | 65 |
age group | 65 |
sore throat | 65 |
within days | 65 |
cov genome | 65 |
time points | 65 |
atypical pneumonia | 64 |
infected person | 64 |
infectious bronchitis | 64 |
cov plpro | 64 |
coronavirus main | 64 |
inhibitors targeting | 64 |
positive selection | 64 |
humoral immune | 64 |
complement activation | 64 |
like coronaviruses | 64 |
copies ml | 64 |
vitro studies | 64 |
potential drug | 64 |
linked immunosorbent | 64 |
observational cohort | 63 |
potential treatment | 63 |
data collection | 63 |
icu admission | 63 |
viral titers | 63 |
cytopathic effect | 63 |
medicinal plants | 63 |
lung cancer | 63 |
epi isl | 63 |
inflammatory cytokine | 63 |
clinical management | 63 |
different countries | 63 |
therapeutic strategies | 63 |
study design | 63 |
herpes simplex | 63 |
reproduction number | 62 |
immune evasion | 62 |
pediatric patients | 62 |
species transmission | 62 |
diagnostic testing | 62 |
cov vaccine | 62 |
study reported | 62 |
community transmission | 62 |
respiratory diseases | 62 |
mrna vaccine | 62 |
murine coronavirus | 62 |
china clinical | 62 |
rapid spread | 62 |
human neutralizing | 62 |
antibody detection | 62 |
african green | 62 |
human infection | 62 |
cells via | 62 |
arabian peninsula | 62 |
novel virus | 62 |
fusion protein | 62 |
national institute | 62 |
high mortality | 62 |
nonhuman primates | 62 |
therapeutic efficacy | 62 |
lymph nodes | 61 |
structural protein | 61 |
copies per | 61 |
drug targets | 61 |
reading frame | 61 |
ct scan | 61 |
hospital admission | 61 |
respiratory system | 61 |
differentially expressed | 61 |
total number | 61 |
international committee | 61 |
ill covid | 61 |
statistical analysis | 60 |
human mers | 60 |
neurologic manifestations | 60 |
high affinity | 60 |
use authorization | 60 |
ma virus | 60 |
patients receiving | 60 |
candidate vaccines | 60 |
receptor usage | 60 |
human primates | 60 |
two groups | 60 |
neutralization assays | 60 |
false negative | 60 |
fecal samples | 60 |
disease caused | 60 |
nonhuman primate | 60 |
genetic diversity | 60 |
disease progression | 60 |
posted september | 60 |
like proteases | 60 |
laboratory diagnosis | 60 |
years old | 60 |
guangdong province | 60 |
close contacts | 59 |
serum antibody | 59 |
indicating person | 59 |
lavage fluid | 59 |
acute kidney | 59 |
cov rbd | 59 |
receptor blockers | 59 |
significant difference | 59 |
family coronaviridae | 59 |
convalescent patients | 59 |
emerging human | 59 |
tract infection | 59 |
inflammatory syndrome | 59 |
icu patients | 59 |
recovered patients | 59 |
targeting sars | 59 |
mild disease | 59 |
antibody levels | 59 |
cellular entry | 58 |
human tissues | 58 |
like sars | 58 |
horseshoe bats | 58 |
cov entry | 58 |
current knowledge | 58 |
chloroquine phosphate | 58 |
fusion peptide | 58 |
critical role | 58 |
viral diseases | 58 |
adult patients | 58 |
chinese center | 58 |
study conducted | 58 |
potential drugs | 58 |
antiviral activities | 58 |
antibody testing | 58 |
coronavirus oc | 58 |
coronavirus nl | 58 |
antiviral therapy | 58 |
septic shock | 58 |
highly expressed | 57 |
high level | 57 |
viral genomes | 57 |
mortality rates | 57 |
mediated isothermal | 57 |
seafood market | 57 |
poor prognosis | 57 |
ct values | 57 |
systemic inflammation | 57 |
whole genome | 57 |
highly contagious | 57 |
virus neutralization | 57 |
drug target | 57 |
data indicate | 57 |
bronchial epithelial | 57 |
better understand | 57 |
catalytic activity | 57 |
induced lung | 57 |
molecule inhibitors | 57 |
cellular immune | 57 |
wild animals | 57 |
future studies | 57 |
fusion inhibitors | 57 |
oropharyngeal swabs | 57 |
patients showed | 56 |
laboratory testing | 56 |
cardiac injury | 56 |
type diabetes | 56 |
myocardial infarction | 56 |
high expression | 56 |
positive samples | 56 |
reference sequence | 56 |
coronavirus receptor | 56 |
situation report | 56 |
york city | 56 |
new insights | 56 |
strand rna | 56 |
significantly lower | 56 |
might also | 56 |
neutralizing monoclonal | 56 |
severely ill | 56 |
species severe | 56 |
coronavirus nucleocapsid | 56 |
elevated levels | 56 |
palm civets | 56 |
whether sars | 56 |
reported cases | 56 |
conformational changes | 56 |
day post | 56 |
immunosorbent assay | 56 |
molecular biology | 55 |
relatively low | 55 |
may result | 55 |
neurological complications | 55 |
bronchitis virus | 55 |
proteolytic cleavage | 55 |
human covs | 55 |
analysis showed | 55 |
positive control | 55 |
supportive care | 55 |
ace inhibitors | 55 |
coronavirus isolated | 55 |
interim guidance | 55 |
secondary structure | 55 |
wastewater treatment | 55 |
antiviral effect | 55 |
respiratory pathogens | 55 |
length human | 55 |
type iii | 55 |
potent inhibitor | 55 |
free energy | 54 |
inhibits sars | 54 |
virus spread | 54 |
low levels | 54 |
higher levels | 54 |
bovine serum | 54 |
prospective study | 54 |
pathological findings | 54 |
recombinant protein | 54 |
interstitial pneumonia | 54 |
cell response | 54 |
rapid detection | 54 |
infected animals | 54 |
cov outbreak | 54 |
will need | 54 |
asymptomatic individuals | 54 |
alveolar macrophages | 54 |
findings suggest | 54 |
sequence analysis | 54 |
humoral response | 53 |
like cleavage | 53 |
pathogenic coronavirus | 53 |
dna vaccines | 53 |
viral fusion | 53 |
dromedary camel | 53 |
potential risk | 53 |
sectional study | 53 |
reverse genetics | 53 |
two viruses | 53 |
viral respiratory | 53 |
enveloped viruses | 53 |
host range | 53 |
genomic sequences | 53 |
will help | 53 |
following sars | 53 |
molecular weight | 53 |
brain barrier | 53 |
face masks | 53 |
protein kinase | 53 |
dependent manner | 53 |
neutralizing activity | 53 |
positive cases | 53 |
probable sars | 53 |
compassionate use | 53 |
syndrome associated | 53 |
simplex virus | 53 |
respiratory coronavirus | 53 |
health authorities | 53 |
based assay | 53 |
transmissible gastroenteritis | 53 |
antiviral compounds | 53 |
severe illness | 53 |
family members | 52 |
oxygen saturation | 52 |
viral pathogenesis | 52 |
asymptomatic sars | 52 |
national health | 52 |
clinical practice | 52 |
complement system | 52 |
inactivated vaccine | 52 |
malayan pangolins | 52 |
scientific community | 52 |
pcr tests | 52 |
nosocomial transmission | 52 |
signaling pathway | 52 |
lung tissues | 52 |
generated using | 52 |
prevent sars | 52 |
one patient | 52 |
specific igg | 52 |
may provide | 52 |
biorxiv doi | 52 |
potential inhibitors | 51 |
coronavirus papain | 51 |
rbd protein | 51 |
throat wash | 51 |
kawasaki disease | 51 |
applied biosystems | 51 |
replication cycle | 51 |
determine whether | 51 |
viral antigen | 51 |
results indicate | 51 |
lung disease | 51 |
rna replication | 51 |
mononuclear cells | 51 |
critical care | 51 |
protein interactions | 51 |
related viruses | 51 |
hr domain | 51 |
hand hygiene | 51 |
multisystem inflammatory | 51 |
common symptoms | 51 |
many countries | 51 |
potential target | 51 |
case study | 51 |
first cases | 50 |
influenza vaccine | 50 |
studies showed | 50 |
remains unclear | 50 |
clinical outcome | 50 |
throughput screening | 50 |
current sars | 50 |
acid detection | 50 |
disease map | 50 |
interferon beta | 50 |
sense rna | 50 |
neutralising antibodies | 50 |
hace mice | 50 |
vitro antiviral | 50 |
angiotensinconverting enzyme | 50 |
substrate binding | 50 |
nasal swab | 50 |
understanding sars | 50 |
million people | 50 |
diagnostic test | 50 |
cysteine protease | 50 |
supplementary material | 50 |
viral spread | 50 |
fda approved | 50 |
adapted sars | 50 |
cov isolates | 50 |
social isolation | 49 |
phase clinical | 49 |
human cell | 49 |
coronaviridae family | 49 |
statistical significance | 49 |
adults hospitalized | 49 |
pulmonary embolism | 49 |
sequence similarity | 49 |
convalescent sera | 49 |
severe symptoms | 49 |
patients without | 49 |
medical records | 49 |
white blood | 49 |
protein data | 49 |
vaccinia virus | 49 |
ongoing clinical | 49 |
organ dysfunction | 49 |
current study | 49 |
cov patients | 49 |
still unclear | 48 |
cov may | 48 |
bcg vaccination | 48 |
treatment strategies | 48 |
virological assessment | 48 |
entry receptor | 48 |
western blot | 48 |
coronavirus genome | 48 |
specific human | 48 |
suspected sars | 48 |
vesicular stomatitis | 48 |
feline infectious | 48 |
new virus | 48 |
test result | 48 |
wuhan city | 48 |
early detection | 48 |
domain complexed | 48 |
united kingdom | 48 |
commons attribution | 48 |
potential vaccine | 48 |
previous study | 48 |
transcription polymerase | 48 |
least two | 48 |
transmission potential | 48 |
ocular surface | 48 |
rhesus macaque | 48 |
palm civet | 47 |
clinical findings | 47 |
throat swabs | 47 |
inactivated sars | 47 |
angiotensin receptor | 47 |
inhibiting sars | 47 |
expressing cells | 47 |
viral proteases | 47 |
cause severe | 47 |
emergency department | 47 |
global public | 47 |
fusion inhibitor | 47 |
like receptors | 47 |
gold standard | 47 |
results obtained | 47 |
proximal origin | 47 |
organ damage | 47 |
may help | 47 |
stomatitis virus | 47 |
acid substitutions | 47 |
anal swabs | 47 |
nsp nsp | 47 |
antibodies targeting | 47 |
infectious peritonitis | 47 |
buffered saline | 47 |
infection rates | 47 |
protein expression | 47 |
pandemic influenza | 47 |
also used | 47 |
per day | 47 |
transmission routes | 46 |
ic values | 46 |
single dose | 46 |
recent advances | 46 |
human igg | 46 |
infected cell | 46 |
data bank | 46 |
hospitalized covid | 46 |
evidence suggests | 46 |
virus vaccine | 46 |
inhibitory effect | 46 |
infect dis | 46 |
cov virus | 46 |
open access | 46 |
ace binding | 46 |
time course | 46 |
essential oils | 46 |
clinical efficacy | 46 |
target cell | 46 |
glass opacities | 46 |
preventive measures | 46 |
available online | 46 |
per well | 46 |
among others | 46 |
virus titers | 46 |
intravenous immunoglobulin | 46 |
protein binding | 46 |
disease course | 46 |
highly specific | 46 |
furin cleavage | 46 |
potent neutralizing | 46 |
virus shedding | 46 |
close proximity | 46 |
mild respiratory | 46 |
determined using | 46 |
health measures | 46 |
highly sensitive | 46 |
adaptive immunity | 46 |
disease pathogenesis | 45 |
sars cases | 45 |
cell activation | 45 |
predictive models | 45 |
infection prevention | 45 |
interspecies transmission | 45 |
human health | 45 |
first reported | 45 |
severe patients | 45 |
drug repositioning | 45 |
host factors | 45 |
will also | 45 |
coronavirus envelope | 45 |
higher affinity | 45 |
current evidence | 45 |
surface stability | 45 |
human host | 45 |
much higher | 45 |
protective efficacy | 45 |
urgently needed | 45 |
van der | 45 |
current status | 45 |
tissue culture | 45 |
spanish flu | 45 |
primate model | 45 |
neutralization test | 45 |
protein sequence | 45 |
heart disease | 45 |
abdominal pain | 45 |
genome replication | 45 |
rna sequencing | 45 |
three different | 45 |
i clinical | 45 |
phylogenetic trees | 45 |
median age | 45 |
pathogenic human | 45 |
patients suffering | 45 |
sequence homology | 45 |
patients will | 45 |
machine learning | 45 |
springer nature | 44 |
mildly symptomatic | 44 |
institutional affiliations | 44 |
environmental factors | 44 |
infected people | 44 |
positive rate | 44 |
express ace | 44 |
high sensitivity | 44 |
published maps | 44 |
using human | 44 |
ic value | 44 |
may occur | 44 |
study found | 44 |
remains neutral | 44 |
national institutes | 44 |
culture supernatants | 44 |
coronavirus nsp | 44 |
cell infection | 44 |
jurisdictional claims | 44 |
basic reproduction | 44 |
significantly reduced | 44 |
severe coronavirus | 44 |
coronavirus vaccines | 44 |
nature remains | 44 |
relative humidity | 44 |
serum antibodies | 44 |
less severe | 44 |
ct findings | 44 |
health commission | 44 |
ravulizumab bsc | 44 |
angiotensin i | 44 |
systemic inflammatory | 44 |
potential targets | 44 |
pcr results | 44 |
main proteinase | 44 |
transmembrane protease | 43 |
narrative review | 43 |
cell type | 43 |
breast milk | 43 |
sequencing data | 43 |
mrna vaccines | 43 |
potential intermediate | 43 |
asymptomatic carrier | 43 |
inflammatory mediators | 43 |
generation sequencing | 43 |
may affect | 43 |
like disease | 43 |
like virus | 43 |
lung inflammation | 43 |
cardiovascular diseases | 43 |
blood mononuclear | 43 |
dendritic cell | 43 |
recent report | 43 |
porcine epidemic | 43 |
genetic recombination | 43 |
disseminated intravascular | 43 |
viral vector | 43 |
storm syndromes | 43 |
based assays | 43 |
calculated using | 43 |
viral particle | 43 |
study population | 43 |
like covs | 43 |
binding pocket | 43 |
per ml | 43 |
asymptomatic infection | 43 |
less toxic | 43 |
patient care | 43 |
antiviral treatment | 43 |
patient samples | 43 |
viral infectivity | 43 |
intravascular coagulation | 43 |
effective vaccine | 43 |
virus strains | 42 |
note springer | 42 |
rhesus monkeys | 42 |
structural analysis | 42 |
positive test | 42 |
consider cytokine | 42 |
docking study | 42 |
human serum | 42 |
hiv protease | 42 |
laboratory tests | 42 |
cruise ship | 42 |
epidemiological data | 42 |
recombinant human | 42 |
direct viral | 42 |
flow cytometry | 42 |
therapeutic drugs | 42 |
also detected | 42 |
standard care | 42 |
care facilities | 42 |
will provide | 42 |
primary human | 42 |
renal failure | 42 |
new drugs | 42 |
potent neutralization | 42 |
phase trial | 42 |
newly discovered | 42 |
recently published | 42 |
immunofluorescence assay | 42 |
igg assay | 42 |
label non | 42 |
systemic lupus | 42 |
early diagnosis | 42 |
virus assembly | 42 |
study protocol | 42 |
recent insights | 42 |
nlrp inflammasome | 42 |
aged years | 42 |
important lessons | 42 |
whole blood | 42 |
lymph node | 42 |
deep learning | 42 |
expression vector | 42 |
positive result | 41 |
first time | 41 |
human immune | 41 |
lupus erythematosus | 41 |
probe sets | 41 |
vivo studies | 41 |
low viral | 41 |
vitro activity | 41 |
natural killer | 41 |
coronavirus fusion | 41 |
physical distancing | 41 |
infected macaques | 41 |
culture medium | 41 |
severely affected | 41 |
recent reports | 41 |
high prevalence | 41 |
epidemiological characteristics | 41 |
emerging coronavirus | 41 |
viral antigens | 41 |
preliminary results | 41 |
two weeks | 41 |
host defense | 41 |
human clinical | 41 |
therapeutic strategy | 41 |
soluble ace | 41 |
suspected cases | 41 |
aged mice | 41 |
accession number | 41 |
total rna | 41 |
coronaviruses sars | 41 |
molecular mechanism | 41 |
negative rt | 41 |
sars pathogenesis | 41 |
infected vero | 41 |
rapid development | 41 |
molecular modeling | 41 |
ct value | 41 |
influenza vaccination | 41 |
epidemic diarrhea | 41 |
substrate specificity | 41 |
health concern | 40 |
virus isolation | 40 |
transmission route | 40 |
highly potent | 40 |
artificial intelligence | 40 |
diagnostic assays | 40 |
lactate dehydrogenase | 40 |
therapeutic potential | 40 |
four genera | 40 |
global initiative | 40 |
air samples | 40 |
therapeutic interventions | 40 |
therapeutic development | 40 |
patients presenting | 40 |
cycle threshold | 40 |
seq data | 40 |
cardiovascular complications | 40 |
virus rna | 40 |
type pneumocytes | 40 |
natural reservoirs | 40 |
review article | 40 |
saliva samples | 40 |
causes severe | 40 |
polyclonal antibodies | 40 |
detecting sars | 40 |
effective vaccines | 40 |
coronavirus pandemic | 40 |
cov ratg | 40 |
asymptomatic infections | 40 |
nasal cavity | 40 |
rna oligonucleotide | 40 |
analyzed using | 40 |
also shown | 40 |
clinical development | 40 |
coronavirus diseases | 40 |
viruses related | 40 |
chinese horseshoe | 40 |
peptide substrates | 40 |
washington state | 40 |
severe lung | 40 |
elderly patients | 40 |
testing positive | 40 |
network analysis | 40 |
human cov | 40 |
nonstructural protein | 40 |
host proteases | 39 |
dimer interface | 39 |
cov transmission | 39 |
mediated immunity | 39 |
human proteins | 39 |
analysis revealed | 39 |
associated pneumonia | 39 |
chronic obstructive | 39 |
whole virus | 39 |
review board | 39 |
diagnostic tools | 39 |
newly emerged | 39 |
blood vessels | 39 |
serological assay | 39 |
proteolytic processing | 39 |
ang ii | 39 |
intrauterine vertical | 39 |
like symptoms | 39 |
significant differences | 39 |
animal host | 39 |
adult inpatients | 39 |
time point | 39 |
ncov infected | 39 |
cd cd | 39 |
global spread | 39 |
may explain | 39 |
relatively high | 39 |
human disease | 39 |
may increase | 39 |
disease outbreak | 39 |
clinically approved | 39 |
influenza infection | 39 |
viral life | 39 |
two cases | 39 |
neuroinvasive potential | 39 |
clinical progression | 39 |
newly identified | 39 |
cerebrovascular disease | 39 |
environmental contamination | 39 |
although sars | 39 |
protective effect | 39 |
increased levels | 39 |
subunit vaccines | 39 |
bone marrow | 39 |
potent antiviral | 39 |
class ii | 39 |
serological testing | 39 |
swab samples | 39 |
sequence data | 39 |
like proteinase | 39 |
plasma samples | 39 |
mers coronaviruses | 39 |
promising results | 39 |
four structural | 39 |
veroe cells | 39 |
cov antibodies | 39 |
mrna expression | 39 |
genome structure | 39 |
igm antibody | 39 |
diagnostic methods | 39 |
disease covid | 39 |
early phase | 39 |
chronic diseases | 39 |
results show | 38 |
febrile infants | 38 |
surface glycoprotein | 38 |
serological investigation | 38 |
illness onset | 38 |
transport medium | 38 |
pilot study | 38 |
pneumonia cases | 38 |
human metapneumovirus | 38 |
animal studies | 38 |
extended data | 38 |
term care | 38 |
cov antibody | 38 |
pathological changes | 38 |
among different | 38 |
comparative analysis | 38 |
protein structure | 38 |
viral membrane | 38 |
acid sphingomyelinase | 38 |
pangolin cov | 38 |
north america | 38 |
new human | 38 |
tissue tropism | 38 |
situ hybridization | 38 |
inactivated virus | 38 |
nucleotide sequence | 38 |
also identified | 38 |
growth factor | 38 |
blood cell | 38 |
lung epithelial | 38 |
subunit vaccine | 38 |
viral activity | 38 |
cysteine residues | 38 |
respiratory secretions | 38 |
spread rapidly | 38 |
natural selection | 38 |
affected patients | 38 |
unclear whether | 38 |
neonates born | 38 |
synonymous mutations | 38 |
maximum likelihood | 38 |
adenovirus type | 38 |
similar results | 38 |
medical center | 38 |
aerosol transmission | 38 |
long term | 38 |
oral mucosa | 38 |
binding motif | 37 |
natural reservoir | 37 |
well known | 37 |
data set | 37 |
obstructive pulmonary | 37 |
active sars | 37 |
receptor angiotensin | 37 |
cov genomes | 37 |
ethics committee | 37 |
data sets | 37 |
clinical evidence | 37 |
antiviral response | 37 |
vaccine induces | 37 |
clinical benefit | 37 |
emerging viruses | 37 |
two studies | 37 |
cytokine responses | 37 |
controlled trials | 37 |
companion animals | 37 |
age groups | 37 |
potent binding | 37 |
least days | 37 |
march th | 37 |
expression profiling | 37 |
inflammatory cells | 37 |
two subunits | 37 |
among adults | 37 |
institutional review | 37 |
gastrointestinal infection | 37 |
aldosterone system | 37 |
umbilical cord | 37 |
vaccine efficacy | 37 |
false positive | 37 |
previous reports | 37 |
critical illness | 37 |
publicly available | 37 |
inhibit viral | 37 |
human intestinal | 37 |
care units | 37 |
oral route | 37 |
immune function | 37 |
protective role | 37 |
liver injury | 37 |
combination therapy | 37 |
syrian hamsters | 37 |
protein sequences | 37 |
higher viral | 37 |
final concentration | 37 |
control strategies | 37 |
plasma treatment | 36 |
candidate drugs | 36 |
antigen presentation | 36 |
coronavirus pathogenesis | 36 |
molecular basis | 36 |
healthy controls | 36 |
times higher | 36 |
confirmed case | 36 |
hydrophobic interactions | 36 |
studies reported | 36 |
standard deviation | 36 |
therapeutic option | 36 |
medical staff | 36 |
human body | 36 |
airway epithelia | 36 |
first two | 36 |
docking studies | 36 |
surface area | 36 |
macrophage activation | 36 |
cell subsets | 36 |
replicase polyprotein | 36 |
acid test | 36 |
phylogenetic analyses | 36 |
virus vaccines | 36 |
previous sars | 36 |
viral transport | 36 |
autoimmune diseases | 36 |
ct imaging | 36 |
small animal | 36 |
study demonstrated | 36 |
first week | 36 |
clinical application | 36 |
spike gene | 36 |
positive rt | 36 |
quantitative rt | 36 |
disease patients | 36 |
nk cells | 36 |
immune activation | 36 |
inflammatory bowel | 36 |
genome analysis | 36 |
posterior oropharyngeal | 36 |
ischemic stroke | 36 |
visiting wuhan | 36 |
healthcare settings | 36 |
research team | 36 |
huanan seafood | 36 |
approved drug | 36 |
igm iga | 36 |
viral pathogens | 36 |
negative test | 36 |
cutaneous manifestations | 36 |
acid sequences | 36 |
genus betacoronavirus | 36 |
mm tris | 36 |
fatality rates | 36 |
blocking sars | 36 |
authors contributed | 36 |
protein palmitoylation | 35 |
domesticated animals | 35 |
several clinical | 35 |
cov vaccines | 35 |
humoral immunity | 35 |
rapidly evolving | 35 |
protein structures | 35 |
corticosteroid treatment | 35 |
past years | 35 |
infectious agents | 35 |
virus detection | 35 |
specimen collection | 35 |
goat anti | 35 |
healthy adults | 35 |
cell membranes | 35 |
domain bound | 35 |
sialic acid | 35 |
binding free | 35 |
clinical manifestation | 35 |
reference genome | 35 |
wuhan outbreak | 35 |
clinical evaluation | 35 |
suspected covid | 35 |
viral attachment | 35 |
membrane vesicles | 35 |
binding affinities | 35 |
influenza data | 35 |
high throughput | 35 |
patients recovered | 35 |
emerging viral | 35 |
nan doi | 35 |
medical history | 35 |
ec values | 35 |
ex vivo | 35 |
genomic sequence | 35 |
first covid | 35 |
studies suggest | 35 |
study sars | 35 |
randomised controlled | 35 |
four patients | 35 |
convalescent serum | 35 |
attenuated vaccines | 35 |
additional file | 35 |
zoonotic coronaviruses | 35 |
respiratory support | 35 |
since sars | 35 |
peptide vaccine | 35 |
human beings | 35 |
secondary antibody | 35 |
nitric oxide | 35 |
median time | 34 |
magnetic resonance | 34 |
fold higher | 34 |
escherichia coli | 34 |
inflammatory diseases | 34 |
sars patient | 34 |
significant increase | 34 |
infection causes | 34 |
study intervention | 34 |
safety profile | 34 |
clinical sensitivity | 34 |
samples obtained | 34 |
nasal epithelial | 34 |
inanimate surfaces | 34 |
coronavirus using | 34 |
graphpad prism | 34 |
camel mers | 34 |
serial dilutions | 34 |
studies also | 34 |
immune cell | 34 |
functional assessment | 34 |
clinical predictive | 34 |
potential anti | 34 |
ground glass | 34 |
camostat mesylate | 34 |
cell immunity | 34 |
acid amplification | 34 |
underlying diseases | 34 |
laboratory findings | 34 |
asymptomatic contact | 34 |
accepted article | 34 |
lessons learned | 34 |
attenuated sars | 34 |
prolonged viral | 34 |
coronavirus detection | 34 |
data obtained | 34 |
common marmoset | 34 |
different sars | 34 |
bacterial infections | 34 |
future research | 34 |
cell proteases | 34 |
stimulated gene | 34 |
recombination events | 34 |
shed light | 34 |
binding domains | 34 |
human dpp | 34 |
oropharyngeal saliva | 34 |
virus load | 34 |
bowel disease | 34 |
using clinical | 34 |
rbd domain | 34 |
smooth muscle | 34 |
inhibitory effects | 34 |
different populations | 34 |
mice transgenic | 34 |
cellular immunity | 34 |
clinical use | 34 |
cytokine levels | 34 |
less likely | 34 |
coronavirus covid | 34 |
reference sequences | 34 |
rapidly spread | 34 |
high dose | 33 |
three patients | 33 |
airway epithelium | 33 |
quality control | 33 |
catalytic domain | 33 |
patients affected | 33 |
mediated immune | 33 |
cytokines chemokines | 33 |
mitochondrial matrix | 33 |
kidney disease | 33 |
infectious cdna | 33 |
bioinformatics analysis | 33 |
cord blood | 33 |
herbal medicines | 33 |
health professionals | 33 |
increasing number | 33 |
species barrier | 33 |
target protein | 33 |
genetic analysis | 33 |
infected persons | 33 |
united arab | 33 |
may represent | 33 |
gastroenteritis virus | 33 |
derived cms | 33 |
also suggested | 33 |
ii clinical | 33 |
transplant recipients | 33 |
convalescent individuals | 33 |
infectious sars | 33 |
arab emirates | 33 |
intestinal epithelial | 33 |
moderate covid | 33 |
possible mechanisms | 33 |
cellular receptors | 33 |
natural infection | 33 |
lysis buffer | 33 |
body fluids | 33 |
based sars | 33 |
observational studies | 33 |
spectrum inhibitors | 33 |
near future | 33 |
acid changes | 33 |
entry inhibitors | 33 |
protocol amendment | 33 |
protein priming | 33 |
analysis using | 33 |
infections caused | 33 |
discovered coronavirus | 33 |
detection rate | 33 |
key residues | 33 |
civet cats | 33 |
zhejiang province | 33 |
community outbreak | 33 |
enteric involvement | 33 |
single cell | 33 |
control study | 33 |
current covid | 33 |
many patients | 33 |
catalytic dyad | 33 |
i interferons | 33 |
receptor antagonist | 33 |
viral vectors | 33 |
like viruses | 33 |
dromedary mers | 33 |
surgical masks | 33 |
genomic data | 33 |
golden syrian | 33 |
ace gene | 33 |
limited number | 33 |
see table | 33 |
mers cov | 33 |
severe pulmonary | 33 |
ps peptide | 33 |
pluripotent stem | 33 |
mutation rates | 32 |
therapeutic intervention | 32 |
mucosal immune | 32 |
significantly associated | 32 |
body weight | 32 |
potential antiviral | 32 |
endothelial dysfunction | 32 |
primer probe | 32 |
also called | 32 |
negative controls | 32 |
blood cells | 32 |
mild cases | 32 |
antiviral agent | 32 |
bat ace | 32 |
nucleotide identity | 32 |
fecal viral | 32 |
viral sequences | 32 |
studies using | 32 |
gastrointestinal manifestations | 32 |
prevent infection | 32 |
protease activity | 32 |
protein gene | 32 |
direct evidence | 32 |
healthy blood | 32 |
natural compounds | 32 |
cell therapy | 32 |
risk assessment | 32 |
emerging novel | 32 |
drugs targeting | 32 |
recombinant adenovirus | 32 |
cov disease | 32 |
two distinct | 32 |
fully understood | 32 |
health officials | 32 |
patients undergoing | 32 |
severe infection | 32 |
protease provides | 32 |
develop severe | 32 |
lead compounds | 32 |
small number | 32 |
pcr analysis | 32 |
five patients | 32 |
serially diluted | 32 |
cov challenge | 32 |
spike glycoproteins | 32 |
lung failure | 32 |
two sars | 32 |
exclusion criteria | 32 |
differential diagnosis | 32 |
reproductive number | 32 |
previously published | 32 |
treating sars | 32 |
throat swab | 32 |
neutralize sars | 32 |
sensory neurons | 32 |
cov strain | 32 |
rna detection | 32 |
subcellular localization | 32 |
clinical diagnosis | 32 |
large scale | 32 |
lower levels | 32 |
site absent | 32 |
vascular endothelial | 32 |
clinical isolates | 32 |
antibody titer | 32 |
vital role | 32 |
mean age | 32 |
host interactions | 31 |
small sample | 31 |
san diego | 31 |
geographical locations | 31 |
molecular diagnosis | 31 |
enrichment analysis | 31 |
thrombotic complications | 31 |
epidemiological studies | 31 |
juvenile animals | 31 |
zebrafish larvae | 31 |
syndrome virus | 31 |
effective antiviral | 31 |
available evidence | 31 |
knee arthroplasty | 31 |
genetic variation | 31 |
ncov contains | 31 |
disease transmission | 31 |
cysteine proteases | 31 |
submitted work | 31 |
active compounds | 31 |
different human | 31 |
diarrhea virus | 31 |
glass opacity | 31 |
avian coronaviruses | 31 |
toxic derivative | 31 |
order nidovirales | 31 |
treatment option | 31 |
optimized dosing | 31 |
virus particle | 31 |
inhibitor targeting | 31 |
ii pneumocytes | 31 |
cytoplasmic tail | 31 |
systems biology | 31 |
transmembrane domain | 31 |
studies will | 31 |
candidate sars | 31 |
med doi | 31 |
final manuscript | 31 |
molecular evolution | 31 |
clinical microbiology | 31 |
different species | 31 |
ec value | 31 |
nucleocapsid proteins | 31 |
cause mild | 31 |
antigen detection | 31 |
molecular patterns | 31 |
human mab | 31 |
reservoir host | 31 |
protein receptor | 31 |
mg twice | 31 |
high degree | 31 |
positive cells | 31 |
immune cross | 31 |
significant reduction | 31 |
fusion core | 31 |
clinical disease | 31 |
host innate | 31 |
dosing design | 31 |
cytokine storms | 31 |
necrotizing encephalopathy | 31 |
igm igg | 31 |
large amounts | 31 |
much lower | 31 |
human receptor | 31 |
masked palm | 31 |
fatal cases | 31 |
drinking water | 31 |
cynomolgus macaques | 31 |
protein synthesis | 31 |
quantitative detection | 31 |
common ancestor | 31 |
single center | 31 |
molecular targets | 31 |
respiratory epithelium | 31 |
sars vaccine | 31 |
major role | 31 |
first line | 31 |
interferon response | 31 |
transcription loop | 31 |
viral strains | 31 |
long time | 31 |
molecular testing | 31 |
young children | 31 |
death rate | 31 |
mouse igg | 30 |
environmental conditions | 30 |
million confirmed | 30 |
many studies | 30 |
cases reported | 30 |
may reflect | 30 |
reduce viral | 30 |
bsc alone | 30 |
bat covs | 30 |
computational methods | 30 |
single nucleotide | 30 |
copy number | 30 |
coronavirus epidemic | 30 |
animal reservoir | 30 |
possible cause | 30 |
ion channel | 30 |
using different | 30 |
hyperimmune plasma | 30 |
different animal | 30 |
temporal dynamics | 30 |
repurposed drugs | 30 |
expressing sars | 30 |
ketoamide inhibitors | 30 |
million cases | 30 |
protective measures | 30 |
developed using | 30 |
cov pathogenesis | 30 |
face mask | 30 |
data available | 30 |
reactive oxygen | 30 |
study period | 30 |
pro inhibitors | 30 |
treat sars | 30 |
differential expression | 30 |
novel coronaviruses | 30 |
engineered human | 30 |
induced acute | 30 |
vaccine targets | 30 |
unexposed individuals | 30 |
based drug | 30 |
like illness | 30 |
outcomes among | 30 |
associated protein | 30 |
inflammatory markers | 30 |
causing covid | 30 |
two independent | 30 |
neutralization activity | 30 |
disease onset | 30 |
fusion mechanism | 30 |
green monkeys | 30 |
patients also | 30 |
generating procedures | 30 |
hace transgenic | 30 |
brain tissue | 30 |
feline coronavirus | 30 |
acute myocardial | 30 |
nucleotide sequences | 30 |
sars vaccines | 30 |
side chain | 30 |
infections among | 30 |
european countries | 30 |
literature search | 30 |
new drug | 30 |
using rt | 30 |
invasive mechanical | 30 |
identify potential | 30 |
mm nacl | 30 |
pneumonia caused | 30 |
pro enzymes | 30 |
based epidemiology | 30 |
infection rate | 30 |
moderate coronavirus | 30 |
step rt | 30 |
highly infectious | 30 |
human sera | 30 |
ongoing pandemic | 30 |
virus binding | 30 |
across different | 30 |
nsp protein | 30 |
multiple organs | 30 |
evolutionary history | 30 |
extraction kit | 29 |
comprehensive review | 29 |
infects human | 29 |
block sars | 29 |
domestic animals | 29 |
within hours | 29 |
serum albumin | 29 |
health system | 29 |
treatment group | 29 |
statistical analyses | 29 |
predict potential | 29 |
carrier transmission | 29 |
predictive value | 29 |
advanced age | 29 |
multiple shedding | 29 |
using two | 29 |
highly effective | 29 |
cov nucleocapsid | 29 |
first wave | 29 |
patients requiring | 29 |
gene source | 29 |
healthy individuals | 29 |
also revealed | 29 |
human protein | 29 |
bovine coronavirus | 29 |
pulmonary pathology | 29 |
measured using | 29 |
among humans | 29 |
viral mrna | 29 |
care providers | 29 |
causing severe | 29 |
high specificity | 29 |
expressed genes | 29 |
days later | 29 |
inclusion criteria | 29 |
short period | 29 |
copy numbers | 29 |
mammalian cells | 29 |
sars infection | 29 |
oxygen species | 29 |
following infection | 29 |
associated molecular | 29 |
propensity score | 29 |
care settings | 29 |
specific antiviral | 29 |
supplementary materials | 29 |
assay using | 29 |
experimentally infected | 29 |
older age | 29 |
oxygen therapy | 29 |
viral detection | 29 |
study using | 29 |
swab specimens | 29 |
host cellular | 29 |
mg dl | 29 |
twice daily | 29 |
access article | 29 |
chinese medicines | 29 |
presumed asymptomatic | 29 |
genomic epidemiology | 29 |
prospective cohort | 29 |
first confirmed | 29 |
naturally occurring | 29 |
bat species | 29 |
full length | 29 |
serum levels | 29 |
dynamics simulation | 29 |
functional characterization | 29 |
rectal swabs | 29 |
ncov pneumonia | 29 |
i ifns | 29 |
wide variety | 29 |
convalescent sars | 29 |
higher mortality | 29 |
genetic sequence | 29 |
mg day | 29 |
ct postponement | 29 |
international concern | 29 |
skilled nursing | 29 |
coronavirus genomes | 29 |
wuhan clinical | 29 |
article distributed | 29 |
also present | 29 |
broad range | 29 |
activation syndrome | 29 |
medical conditions | 29 |
plaque reduction | 29 |
sense single | 29 |
human antibody | 29 |
among healthcare | 29 |
zoonotic transmission | 29 |
exact test | 29 |
developing severe | 29 |
antiviral properties | 28 |
full genome | 28 |
vast majority | 28 |
luciferase activity | 28 |
medicinal chemistry | 28 |
hyaline membrane | 28 |
md simulations | 28 |
additional studies | 28 |
gut microbiota | 28 |
current outbreak | 28 |
rna expression | 28 |
cov viral | 28 |
future outbreaks | 28 |
zoonotic origin | 28 |
inhibited sars | 28 |
iga antibodies | 28 |
transmission rate | 28 |
host proteins | 28 |
inactivated whole | 28 |
healthcare professionals | 28 |
without permission | 28 |
diamond princess | 28 |
china coronavirus | 28 |
covalent bond | 28 |
fully human | 28 |
coronavirus family | 28 |
genbank accession | 28 |
community spread | 28 |
ucsf chimera | 28 |
severe forms | 28 |
infectious agent | 28 |
west nile | 28 |
tyrosine kinase | 28 |
fold change | 28 |
first report | 28 |
wastewater samples | 28 |
may induce | 28 |
cell cycle | 28 |
protease cleavage | 28 |
original author | 28 |
coronavirus strains | 28 |
two days | 28 |
two main | 28 |
short time | 28 |
infected cases | 28 |
drug candidate | 28 |
vero cell | 28 |
obtained using | 28 |
virus genome | 28 |
shedding routes | 28 |
immunological studies | 28 |
different stages | 28 |
constructed using | 28 |
tissue sections | 28 |
ace interaction | 28 |
pneumonia clinical | 28 |
associated sars | 28 |
among sars | 28 |
sperm banking | 28 |
diseases like | 28 |
first sars | 28 |
genome encodes | 28 |
allowed without | 28 |
receptor expression | 28 |
scoping review | 28 |
symptom resolution | 28 |
cancer cells | 28 |
vaccine platform | 28 |
many cases | 28 |
olfactory dysfunction | 28 |
cell proliferation | 28 |
inflammatory drugs | 28 |
adaptive evolution | 28 |
way anova | 28 |
coronary artery | 28 |
increases infectivity | 28 |
lethal disease | 28 |
pediatric sars | 28 |
soluble human | 28 |
clinical severity | 28 |
pathogenic viruses | 28 |
tract specimens | 28 |
western medicine | 28 |
older people | 28 |
novel severe | 28 |
nuclear factor | 28 |
antibodies directed | 28 |
new cases | 28 |
leader sequence | 28 |
chinese herbal | 28 |
human bronchial | 28 |
time period | 28 |
temporal profiles | 28 |
genome composition | 28 |
human organs | 28 |
reuse allowed | 28 |
hydroxyl group | 28 |
different parts | 28 |
peptide substrate | 28 |
rapid transmission | 27 |
st century | 27 |
chronic respiratory | 27 |
different cell | 27 |
iii clinical | 27 |
tissue samples | 27 |
rna polymerases | 27 |
site residues | 27 |
ace levels | 27 |
human antibodies | 27 |
different organs | 27 |
antibody therapy | 27 |
neutralising antibody | 27 |
infected patient | 27 |
treat patients | 27 |
igg elisa | 27 |
human primate | 27 |
protein may | 27 |
rna binding | 27 |
multiorgan failure | 27 |
mediated inflammatory | 27 |
beta coronavirus | 27 |
faecal samples | 27 |
host species | 27 |
der waals | 27 |
novel therapeutic | 27 |
neurological involvement | 27 |
protein induces | 27 |
retrospective review | 27 |
important roles | 27 |
acid testing | 27 |
clinical testing | 27 |
rapid diagnostic | 27 |
trained immunity | 27 |
patients diagnosed | 27 |
infection among | 27 |
pangolin origin | 27 |
stimulating factor | 27 |
extracellular traps | 27 |
may act | 27 |
specimens collected | 27 |
cytopathic effects | 27 |
symptomatic individuals | 27 |
three days | 27 |
turnaround time | 27 |
venous thromboembolism | 27 |
barr virus | 27 |
acute sars | 27 |
antibody assays | 27 |
studies revealed | 27 |
interquartile range | 27 |
provide evidence | 27 |
neutralisation assays | 27 |
vaccine platforms | 27 |
ii receptor | 27 |
pathogenic mechanisms | 27 |
fetal bovine | 27 |
conserved among | 27 |
coronavirus cl | 27 |
ace shedding | 27 |
chemoattractant protein | 27 |
old man | 27 |
brain organoids | 27 |
using molecular | 27 |
peptide bond | 27 |
possible explanation | 27 |
cells using | 27 |
therapeutic agent | 27 |
specific sars | 27 |
among covid | 27 |
controlled clinical | 27 |
peritonitis virus | 27 |
human brain | 27 |
architect sars | 27 |
nile virus | 27 |
selection pressure | 27 |
will likely | 27 |
nursing facility | 27 |
may serve | 27 |
plasma transfusion | 27 |
pivotal role | 27 |
transmitted via | 27 |
macrophage responses | 27 |
au ml | 27 |
pharyngeal swabs | 27 |
dis doi | 27 |
force field | 27 |
mhc class | 27 |
endocytic pathway | 27 |
reported confirmed | 27 |
provide insight | 27 |
six patients | 27 |
viral structural | 27 |
improves outcome | 27 |
plasmacytoid dendritic | 27 |
virus cell | 27 |
sars pneumonia | 27 |
humoral responses | 26 |
domain iii | 26 |
takes place | 26 |
block viral | 26 |
highly susceptible | 26 |
patient cohort | 26 |
coronavirus causing | 26 |
recently reported | 26 |
hydrogen bonding | 26 |
specific cell | 26 |
drug screening | 26 |
health systems | 26 |
membrane formation | 26 |
may include | 26 |
molecular evolutionary | 26 |
nsp complex | 26 |
patients randomized | 26 |
will require | 26 |
time horizon | 26 |
pulmonary edema | 26 |
different time | 26 |
mediated endocytosis | 26 |
virus strain | 26 |
ongoing wuhan | 26 |
salt bridge | 26 |
neutrophil extracellular | 26 |
inflammatory activity | 26 |
animal reservoirs | 26 |
comparative study | 26 |
electron microscope | 26 |
vaccination strategies | 26 |
covalent docking | 26 |
active sites | 26 |
dimer levels | 26 |
existing drugs | 26 |
information regarding | 26 |
receiving hydroxychloroquine | 26 |
viral polymerase | 26 |
rna levels | 26 |
sustentacular cells | 26 |
sars drugs | 26 |
neutralizing anti | 26 |
andrological services | 26 |
laboratory confirmed | 26 |
resonance imaging | 26 |
pandemic caused | 26 |
virus clearance | 26 |
induced dimerization | 26 |
ace may | 26 |
monocyte chemoattractant | 26 |
cov proteins | 26 |
lymphocyte ratio | 26 |
regarding sars | 26 |
homology modelling | 26 |
parainfluenza virus | 26 |
pg ml | 26 |
storm syndrome | 26 |
written informed | 26 |
intermediate animal | 26 |
conjunctival secretions | 26 |
combat covid | 26 |
antiviral therapies | 26 |
kidney cells | 26 |
reduced viral | 26 |
potent inhibitors | 26 |
recognition receptors | 26 |
chest radiograph | 26 |
also demonstrated | 26 |
commons licence | 26 |
recombination event | 26 |
respiratory pathogen | 26 |
rnadependent rna | 26 |
positive pcr | 26 |
another important | 26 |
hpa axis | 26 |
human covid | 26 |
lymphocyte counts | 26 |
health crisis | 26 |
readily available | 26 |
specific treatment | 26 |
viral genomic | 26 |
therapeutic approaches | 26 |
medical countermeasures | 26 |
green monkey | 26 |
ace mrna | 26 |
prevent covid | 26 |
viral genes | 26 |
first patient | 26 |
viral invasion | 26 |
potential conflict | 26 |
mini kit | 26 |
seasonal influenza | 26 |
clinical presentations | 26 |
using sars | 26 |
prior infection | 26 |
macaque model | 26 |
cell lysates | 26 |
potential inhibitor | 26 |
studies suggested | 26 |
virus fusion | 26 |
asymptomatic transmission | 25 |
ligand binding | 25 |
promising drug | 25 |
functional basis | 25 |
optical density | 25 |
endosomal ph | 25 |
rna dependent | 25 |
people worldwide | 25 |
glycosylation sites | 25 |
infection diagnosis | 25 |
hospital stay | 25 |
mass testing | 25 |
old male | 25 |
nine pregnant | 25 |
creatine kinase | 25 |
media briefing | 25 |
sensitive detection | 25 |
highly purified | 25 |
adults aged | 25 |
grade soluble | 25 |
viral disease | 25 |
research group | 25 |
expressing human | 25 |
transmission via | 25 |
symptomatic patient | 25 |
regression model | 25 |
mechanisms underlying | 25 |
eye protection | 25 |
serum dilution | 25 |
critical covid | 25 |
nationwide analysis | 25 |
point mutations | 25 |
clinical therapies | 25 |
host interactome | 25 |
olfactory sensory | 25 |
clinical settings | 25 |
different geographical | 25 |
candidate vaccine | 25 |
literature review | 25 |
cells may | 25 |
pro cleavage | 25 |
may require | 25 |
coronavirus study | 25 |
potential evidence | 25 |
lung function | 25 |
antibodies may | 25 |
gene ontology | 25 |
productive infection | 25 |
logistic regression | 25 |
will continue | 25 |
still unknown | 25 |
research groups | 25 |
important target | 25 |
contact precautions | 25 |
live sars | 25 |
tissues using | 25 |
transcription factors | 25 |
drug treatment | 25 |
amniotic fluid | 25 |
main target | 25 |
findings indicate | 25 |
expressing ace | 25 |
limited data | 25 |
attenuated virus | 25 |
mtase activity | 25 |
infect human | 25 |
virus challenge | 25 |
chest computed | 25 |
guinea pigs | 25 |
ray structure | 25 |
human infections | 25 |
likely due | 25 |
persistent fecal | 25 |
experimental infection | 25 |
antibody blocking | 25 |
continuous variables | 25 |
protein rbd | 25 |
rapid test | 25 |
neutralization capacity | 25 |
mass spectrometry | 25 |
recent evidence | 25 |
primate models | 25 |
serologic assays | 25 |
based design | 25 |
significantly increased | 25 |
natural host | 25 |
increased expression | 25 |
study revealed | 25 |
binding mode | 25 |
based analysis | 25 |
remains unknown | 25 |
detection methods | 25 |
terminal region | 25 |
blood group | 25 |
genetically modified | 25 |
encephalitis associated | 25 |
systematic reviews | 25 |
also contribute | 25 |
results demonstrate | 25 |
beneficial effects | 25 |
therapeutic approach | 25 |
expression profile | 25 |
princess cruise | 25 |
viral surface | 25 |
linear regression | 25 |
older patients | 25 |
well plate | 25 |
young adults | 25 |
alveolar type | 25 |
disease spread | 25 |
also play | 25 |
pandemic covid | 25 |
domestic cats | 25 |
randomized trial | 25 |
electron density | 25 |
plasma levels | 25 |
chloroquine hydroxychloroquine | 25 |
center experience | 25 |
hierarchical clustering | 25 |
vectored covid | 25 |
escape mutants | 25 |
positive correlation | 25 |
significant role | 25 |
two types | 25 |
secondary antibodies | 24 |
severe outcomes | 24 |
polybasic cleavage | 24 |
transport media | 24 |
human trial | 24 |
pandemic potential | 24 |
low prevalence | 24 |
coronavirus isolates | 24 |
among individuals | 24 |
heart rate | 24 |
china sars | 24 |